Yes the crystalisation problem remained to be solved even if Lederle had chosen to abandon bisantrene because their CEO hated the colour orange.
This crystalisation problem is now solved, the IP is vastly stronger and broader, and we now know and can advance the massive CPACS and m6A RNA opportunities.
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?, page-36
-
- There are more pages in this discussion • 356 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.54 |
Change
-0.065(4.05%) |
Mkt cap ! $262.4M | |||
| Open | High | Low | Value | Volume |
| $1.62 | $1.62 | $1.51 | $261.3K | 168.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 30000 | $1.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2000 | 1 |
View Market Depth
| Last trade - 15.59pm 09/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |